President Donald Trump announced an agreement with drugmakers Novo Nordisk and Eli Lilly to reduce the monthly out-of-pocket cost of their GLP-1 weight loss drugs, Wegovy and Zepbound, to between $50 and $350. Currently priced over $1,000, these drugs will become more affordable through the government’s TrumpRx platform and potential Medicare coverage. However, it’s unclear how many will benefit, especially since Medicare does not cover weight loss drugs alone. The administration anticipates new pricing to be available by year-end, alongside similar agreements with Pfizer and AstraZeneca.
